Open original FDA record ↗Recall record
- FDA identifier
- Z-0355-2027
- Company in FDA record
- Remel, Inc
- FDA classification date
- Nov 3, 2026
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 17, 2026
- Recall classification
- Class II
Reason stated in the source
Affected lot did not meet specifications. Product may report false susceptibility to antifungal agents, specifically within the Azole family.
Source facts
- Action
- The firm began notifying affected customers on October 19, 2026. Customers were instructed to notify any personnel who needed to be aware of the issue. Customers should review previously reported susceptibility results generated using the affected lot and assess whether retesting is appropriate. Customers should destroy any remaining inventory of the affected lot. Do not use it for any clinical laboratory testing. Customers should complete and return the acknowledgement form accompanying the letter. Firm will replace product or issue credit. If you have any questions, please contact our Technical Services Department at 800-255-6730 (US) or email microbiology.ts.us@thermofisher.com. You should complete the accompanying Acknowledgment Form upon receipt and return to MBD.vigilance@thermofisher.com
- Initiated
- 2026-10-19
- Root cause
- Under Investigation by firm
- Distribution
- Worldwide - US Nationwide distribution in the states of MA and CA. The countries of India, Saudi Arabia, UK.
- Recall number
- Z-0355-2027
- Recall status
- Open, Classified
- CDRH record ID
- 223399
- FDA classified
- 2026-11-03
- Recall event number
- 100139